Skip to main content
SpringerLink
Log in

Viral Dynamic Modeling and Simulations in HIV and Hepatitis C

  • Chapter
  • First Online:
Clinical Trial Simulations

Part of the book series: AAPS Advances in the Pharmaceutical Sciences Series ((AAPS,volume 1))

  • 2540 Accesses

Abstract

Viral dynamic modeling and simulations have dramatically improved our understanding of the life cycle of chronic viral infections such as HIV and hepatitis C virus (HCV). These viral dynamic models account for the interaction between virus and host, and how antiviral agents interfere with this system thereby reducing the measured viral load and clearing the virus. In this chapter, the basic viral dynamic modeling concepts such as the predator–prey interaction introduced by Lotka–Volterra, the basic reproductive ratio (R 0), the reproductive minimal inhibitory concentration (RMIC) and the physiologically based viral eradication boundary are explained and illustrated by viral dynamic models developed for HIV and HCV. Examples are presented showing how simulations based on these models can be used to better understand the virus–host system and the mechanism of action of antiviral drugs, and to optimize treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 229.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Anderson RM, May RM (1997a) Population biology of infectious diseases: part 1. Nature 280:361–367

    Article  Google Scholar 

  • Anderson RM, May RM (1997b) Population biology on infectious diseases: part 2. Nature 280:455

    Google Scholar 

  • Beal SL, Sheiner LB (1998) NONMEM users guides. NONMEM Project Group. University of California, San Francisco

    Google Scholar 

  • Bernardin F, Tobler L, Walsh I, Williams JD, Busch M, Delwart E (2008) Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia. Hepatology 47:1446–1452

    Article  PubMed  CAS  Google Scholar 

  • Bonhoeffer S (1998) Models of viral kinetics and drug resistance in HIV-1 infection. AIDS Patient Care STDS 12:769–774

    Article  PubMed  CAS  Google Scholar 

  • Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94:6971–6976

    Article  PubMed  CAS  Google Scholar 

  • Callaway DS, Perelson AS (2002) HIV-1 infection and low steady state viral loads. Bull Math Biol 64:29–64

    Article  PubMed  Google Scholar 

  • Chan P, Jacqmin P, Lavielle M, McFadyen L, Weatherley B (2009) Population pharmacokinetic-pharmacodynamic-viral dynamics modeling of maraviroc monotherapy data using MONOLIX, PAGE 18, Abstract 1517. http://www.page-meeting.org/?abstract=1517 october 2010

  • Chan P, Jacqmin P, Lavielle M, McFadyen L, Weatherley B (2010) The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects. J Pharmacokin Pharmacodyn (submitted for publication)

    Google Scholar 

  • Colombatto P, Civitano L, Oliveri F, Coco B, Ciccorossi P, Flichman D, Campa M, Bonino F, Brunetto MR (2003) Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase. Antivir Ther 8:519–530

    PubMed  CAS  Google Scholar 

  • Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98:6895–6900

    Article  PubMed  CAS  Google Scholar 

  • Dahari H, Lo A, Ribeiro RM, Perelson AS (2007) Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol 247:371–381

    Article  PubMed  CAS  Google Scholar 

  • Delyon B, Lavielle M, Moulines E (1999) Convergence of a stochastic approximation version of the EM algorithm. Ann Stat 27:94–128

    Article  Google Scholar 

  • Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432:922–924

    Article  PubMed  CAS  Google Scholar 

  • Fätkenheuer G, Pozniak AL, Johnson MA, Plettenberg A, Staszewski S, Hoepelman AIM, Saag MS, Goebel FD, Rockstroh JK, Dezube BJ, Jenkins TM, Medhurst C, Sullivan JF, Ridgway C, Abel S, James IT, Youle M, van der Ryst E (2005) Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 11:1170–1172

    Article  PubMed  Google Scholar 

  • Ferguson NM, Donnelly CA, Hooper J, Ghani AC, Fraser C, Bartley LM, Rode RA, Vernazza P, Lapins D, Mayer SL (2005) Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients. J R Soc Interface 2:349–363

    Article  PubMed  CAS  Google Scholar 

  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982

    Article  PubMed  CAS  Google Scholar 

  • Funk GA, Fischer M, Joos B, Opravil M, Günthard H, Ledergerber B, Bonhoeffer S (2001) Quantification of in vivo replicative capacity of HIV-1 in different compartments of infected cells. J Acquir Immune Defic Syndr 26:397–404

    PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; Pegasys International Study Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355

    Article  Google Scholar 

  • Heffernan JM, Smith RJ, Wahl LM (2005) Perspectives on the basic reproductive ratio. J R Soc Interface 2:281–293

    Article  PubMed  CAS  Google Scholar 

  • Ho DD, Neumann AU, Perelson AS et al (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123–126

    Article  PubMed  CAS  Google Scholar 

  • Huang Y, Rosenkranz SL, Wu H (2003) Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. Math Biosci 184:165–186

    Article  PubMed  CAS  Google Scholar 

  • Huang Y, Liu D, Wu H (2006) Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics 62:413–423

    Article  PubMed  Google Scholar 

  • Jacqmin P, McFadyen L, Wade JR (2010) Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling. J. Pharmacokinet Pharmacodyn. 2010 Apr; 37(2):157–77. Epub 2010 Mar 4

    Google Scholar 

  • Khan AZ, Mudan SS (2007) Liver regeneration: mechanisms, mysteries and more. ANZ J Surg 77:9–14

    Article  PubMed  Google Scholar 

  • Kuhn E, Lavielle M (2005) Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 49:1020–1038

    Article  Google Scholar 

  • Lau JYN, Tam RC, Liang TJ, Hong Z (1996) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:1002–1009

    Article  Google Scholar 

  • Layden JE, Layden TJ (2002) Viral kinetics of hepatitis C: new insights and remaining limitations. Hepatology 35:967–970

    Article  PubMed  Google Scholar 

  • Layden TJ, Layden JE, Ribeiro RM, Perelson AS (2003) Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin Liver Dis 7:163–178

    Article  PubMed  Google Scholar 

  • Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 37:1343–1350

    Article  PubMed  CAS  Google Scholar 

  • Layden-Almer JE, Cotler SJ, Layden TJ (2006) Viral kinetics in the treatment of chronic hepatitis C. J Viral Hepat 13:499–504

    Article  PubMed  Google Scholar 

  • Liou TC, Chang TT, Young KC, Lin XZ, Lin CY, Wu HL (1992) Detection of HCV RNA in saliva, urine, seminal fluid and ascites. J Med Virol 37:203–209

    Article  Google Scholar 

  • Manns MP et al (2001) Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958–965

    Article  PubMed  CAS  Google Scholar 

  • Mc Sween RNM, Anthony PP, Scheuer PJ (1987) Pathology of the liver, 2nd edn. Churchill Livingstone, Edinburgh

    Google Scholar 

  • Michalopoulos GK, DeFrances MC (1997) Liver regeneration. Science 276:60–66

    Article  PubMed  CAS  Google Scholar 

  • MONOLIX software supported by the MONOLIX Group. http://www.monolix.org/ october 2010

  • National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002–June 10–12, 2002

    Google Scholar 

  • Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107

    Article  PubMed  CAS  Google Scholar 

  • Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, Perelson AS, Layden TJ (2000) Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182:28–35

    Article  PubMed  CAS  Google Scholar 

  • Nowak MA, Anderson RM, Boerlijst MC, Bonhoeffer S, May RM, McMichael AJ (1996) HIV-1 evolution and disease progression. Science 274:1008–1011

    Article  PubMed  CAS  Google Scholar 

  • Nowak MA, Bonhoeffer S, Shaw GM, May RM (1997) Antiviral drug treatment: dynamics of resistance in free virus and infected cell population. J Theor Biol 184:203–217

    Article  PubMed  CAS  Google Scholar 

  • Nowak MA, May RM (2000) Virus dynamics: mathematical principles of immunology and virology. Oxford University Press, New York

    Google Scholar 

  • Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133:21–30

    Article  PubMed  CAS  Google Scholar 

  • Pawlotsky JM et al (2004) Antiviral action of ribavirin in chronic hapatitis C. Gastroenterology 126:703–714

    Article  PubMed  CAS  Google Scholar 

  • Perelson AS (2002) Modeling viral and immune system dynamics. Nat Rev Immunol 2:28–36

    Article  PubMed  CAS  Google Scholar 

  • Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life span, and viral generation time. Science 271:1582–1586

    Article  PubMed  CAS  Google Scholar 

  • Perelson AS, Essunger P, Cao Y et al (1997) Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 387:188–191

    Article  PubMed  CAS  Google Scholar 

  • Perelson AS, Herrmann E, Micol F, Zeuzem S (2005) New kinetic models for the hepatitis C virus. Hepatology 42:749–754

    Article  PubMed  CAS  Google Scholar 

  • Phillips A, Youle M, Johnson M, Loveday C (2001) Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development. AIDS 15:2211–2220

    Article  PubMed  CAS  Google Scholar 

  • Pomfret EA, Pomposelli JJ, Gordon FD, Erbay N, Lyn Price L, Lewis WD, Jenkins RL (2003) Liver regeneration and surgical outcome in donors of right-lobe liver grafts. Transplantation 76:5–10

    Article  PubMed  Google Scholar 

  • Rong L, Zhilan Feng Z, Perelson A (2007) Emergence of HIV-1 drug resistance during antiretroviral treatment. Bull Math Biol 69:2027–2060

    Article  PubMed  Google Scholar 

  • Rosario MC, Poland B, Sullivan J, Westby M, van der Ryst E (2006) A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc. J Acquir Immune Defic Syndr 42:183–191

    Article  PubMed  CAS  Google Scholar 

  • Samson A, Lavielle M, Mentré F (2007) The SAEM algorithm for group comparison tests in longitudinal data analysis based on non-linear mixed-effects model. Stat Med 26:4860–4875

    Article  PubMed  Google Scholar 

  • Sherlock S, Dooley J (1998) Disease of the liver and biliary system. Blackwell Science, Oxford

    Google Scholar 

  • Snoeck E, Wade JR, Duff F, Lamb M, Jorga K (2006) Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 62:699–709

    Article  PubMed  CAS  Google Scholar 

  • Snoeck E, Laveille M, Chanu P, Jorga K, Frey N (2008) The challenge of modelling hepatitis C virus dynamics after long term treatment: application of Monolix. Presented at PAGE 17, Abstract 1348. http://www.page-meeting.org/?abstract=1348 october 2010

  • Snoeck E, Chanu P, Lavielle M, Jacqmin P, Jonsson EN, Jorga K, Goggin T, Grippo J, Jumbe NL, Frey N (2010) A comprehensive hepatitis C viral kinetic model explaining cure. Clin Pharmacol Ther (accepted for publication). Clinical Pharmacology & Therapeutics 87:706–713 (June 2010) | doi:10.1038/clpt.2010.35

    Google Scholar 

  • Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171

    Article  Google Scholar 

  • Wahl LM, Nowak MA (2000) Adherence and drug resistance: predictions for therapy outcome. Proc Biol Sci 267:835–843

    Article  PubMed  CAS  Google Scholar 

  • Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH et al (1995) Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117–122

    Article  PubMed  CAS  Google Scholar 

  • Wood A, Armour D (2005) The discovery of the CCR5 receptor antagonist, UK-427, 857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem 43:239–271

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (2008) Hepatitis C. http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed 15 Sept 2008

  • Wu H, Zhao C, Liang H (2004) Comparison of linear, nonlinear and semi parametric models for estimating HIV dynamic parameters. Biom J 46:233–245

    Article  Google Scholar 

  • Wu H, Huang Y, Acosta EP, Park JG, Yu S, Rosenkranz SL, Kuritzkes DR, Eron JJ, Perelson AS, Gerber JG (2006) Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence. J Pharmacokinet Pharmacodyn 33:399–419

    Article  PubMed  CAS  Google Scholar 

  • Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH (1996) Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125:634–639

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S (2001) The kinetics of hepatitis C virus infection. Clin Liver Dis 5:917–930

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Herrmann E (2002) Dynamics of hepatitis C virus infection. Ann Hepatol 1:56–63

    PubMed  Google Scholar 

  • Zoulim F et al (1998) Ribavirin monotherapy in patients with chronic hepatitis C: a retrospective study of 95 patients. J Viral Hepat 5:193–198

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Our viral dynamic modeling projects in HIV and Hepatitis C have been performed in collaboration with respectively Pfizer Global Research and Development, Sandwich, UK and F. Hoffmann-La Roche, Basel, Switzerland. We therefore thank Lynn McFadyen, Phylinda Chan, Barry Weatherley, Scott Marshall and Peter Milligan from Pfizer and Pascal Chanu, Karin Jorga, Timothy Goggin, Joe Grippo, Nelson L. Jumbe and Nicolas Frey from Hoffmann-La Roche for their contributions and scientific support. We thank Niclas Jonsson and Janet Wade, our Colleagues at Exprimo, for their contribution. We also thank Marc Lavielle from INRIA, Paris, France for his help with the implementation of our viral dynamic models into the MONOLIX software.

Author information

Authors and Affiliations

  1. Exprimo NV, Mechelen, Belgium

    Philippe Jacqmin

Authors
  1. Philippe Jacqmin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Snoeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Jacqmin .

Editor information

Editors and Affiliations

  1. Department of Advanced Modeling & Simula, Janssen Research & Development, LLC, Route 202 S. 920, Raritan, 08869, New Jersey, USA

    Holly H. C. Kimko

  2. Dept. Biopharmaceutical Sciences, University of California, San Francisco, Parnassus Ave. 513, San Francisco, 94143-0446, California, USA

    Carl C. Peck

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jacqmin, P., Snoeck, E. (2011). Viral Dynamic Modeling and Simulations in HIV and Hepatitis C. In: Kimko, H., Peck, C. (eds) Clinical Trial Simulations. AAPS Advances in the Pharmaceutical Sciences Series, vol 1. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7415-0_11

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation